Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses

Cancer Research

Volumn 63, Issue 22, 2003, Pages 7942-7949

  Hodge, James W ^a   Poole, Diane J ^a   Aarts, Wilhelmina M ^a   Yafal, Alicia Gómez ^b   Gritz, Linda ^b   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Therion Biologics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENETIC CODE; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA; VACCINIA VIRUS;

ANIMALS; ANTIGENS, CD58; ANTIGENS, CD80; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CHICK EMBRYO; FEMALE; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED C57BL; TRANSGENES; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 0344412934     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Grosenbach, D. W., Barrientos, J. C., Schlom, J., and Hodge, J. W. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res., 61: 4497-4505, 2001.
2. Hodge, J. W., Grosenbach, D. W., and Schlom, J. Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity. Cancer Detect. Prev., 26: 275-291, 2002.
3. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian poxvirus to enhance T-cell immunity and antitumor responses. Vaccine. 15: 759-768, 1997.
4. Greiner, J. W., Zeytin, H., Anver, M. R., and Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res., 62: 6944-6951, 2002.
5. Sutter, G., and Moss, B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev. Biol. Stand., 84: 195-200, 1995.
6. Moss, B., Carroll, M. W., Wyatt, L. S., Bennink, J. R., Hirsch, V. M., Goldstein, S., Elkins, W. R., Fuerst, T. R., Lifson, J. D., Piatak, M., Restifo, N. P., Overwijk, W., Chamberlain, R., Rosenberg, S. A., and Sutter, G. Host range restricted, nonreplicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol., 397: 7-13, 1996.
7. Johnston, M. I., and Flores, J. Progress in HIV vaccine development. Curr. Opin. Pharmacol., 1: 504-510, 2001.
8. Barnett, S. W., Klinger, J. M., Doe, B., Walker, C. M., Hansen, L., Duliege, A. M., and Sinangil, F. M. Prime-boost immunization strategies against HIV. AIDS Res. Hum. Retroviruses, 14 (Suppl. 3): S299-309, 1998.
9. Akagi, J., Hodge, J. W., McLaughlin, J. P., Gritz, L., Mazzara, G., Kufe, D., Schlom, J., and Kantor, J. A. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunother., 20: 38-47, 1997.
10. Hodge, J. W., Schlom, J., Donohue, S. J., Tomaszewski, J. E., Wheeler, C. W., Levine, B. S., Gritz, L., Panicali, D., and Kantor, J. A. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int. J. Cancer, 63: 231-237, 1995.
11. Hodge, J. W., McLaughlin, J. P., Abrams, S. I., Shupert, W. L., Schlom, J., and Kantor, J. A. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res., 55: 3598-3603. 1995.
12. Kass, E., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., and Greiner, J. W. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res., 59: 676-683, 1999.
13. Hodge, J. W., McLaughlin, J. P., Kantor, J. A., and Schlom, J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine, 15: 759-768, 1997.
14. Zhu, M. Z., Marshall, J., Cole, D., Schlom, J., and Tsang, K. Y. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res., 6: 24-33, 2000.
15. Marshall, J., Hoyer, R., Toomey, M., Faraguna, K., Chang, P., Richmond, E., Pedicano, J., Gehan, E., Peck, R., Arlen, P., Tsang, K., and Schlom, J. Phase I study in cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen responses. J. Clin. Oncol., 18: 3964-3973, 2000.
16. Eder, J. P., Kantoff, P. W., Roper, K., Xu, G. X., Bubley, G. J., Boyden, J., Gritz, L., Mazzara, G., Oh, W. K., Arlen, P., Tsang, K. Y., Panicali, D., Schlom, J., and Kufe, D. W. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res., 6: 1632-1638, 2000.
17. Kass, E., Panicali, D. L., Mazzara, G., Schlom, J., and Greiner, J. W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res., 61: 206-214, 2001.
18. Marshall, J. L., Hawkins, M. J., Tsang, K. Y., Richmond, E., Pedicano, J. E., Zhu, M. Z., and Schlom, J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol., 17: 332-337, 1999.
19. Irvine, K. R., Chamberlain, R. S., Shulman, E. P., Surman, D. R., Rosenberg, S. A., and Restifo, N. P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst., 89: 1595-1601, 1997.
20. Chamberlain, R. S., Carroll, M. W., Bronte, V., Hwu, P., Warren, S., Yang, J. C., Nishimura, M., Moss, B., Rosenberg, S. A., and Restifo, N. P. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res., 56: 2832-2836, 1996.
21. Hodge, J. W., Sabzevari, H., Korenz, M. G. O., Gomez Yafal, A., Gritz, L., and Schlom, J. A triad of costimulatory molecules synergize to amplify T cell activation. Cancer Res., 59: 5800-5807, 1999.
22. Hodge, J. W., Rad, A. N., Grosenbach, D. W., Sabzevari, H., Yafal, A. G., Gritz, L., and Schlom, J. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J. Natl. Cancer Inst., 92: 1228-1239, 2000.
23. Chakrabarti, S., Sisler, J. R., and Moss, B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques, 23: 1094-1097, 1997.
24. Perkus, M. E., Piccini, A., Lipinskas, B. R., and Paoletti, E. Recombinant vaccinia virus: immunization against multiple pathogens. Science (Wash. DC), 229: 981-984, 1985.
25. Schmitt, J. F., and Stunnenberg, H. G. Sequence and transcriptional analysis of the vaccinia virus HindIII 1 fragment. J. Virol., 62: 1889-1897, 1988.
26. Gritz, L., Destree, A., Cormier, N., Day, E., Stallard, V., Caiazzo, T., Mazzara, G., and Panicali, D. Generation of hybrid genes and proteins by vaccinia virus mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol., 64: 5948-5957, 1990.
27. Eades-Pemer, A. M., van der Putten, H., Hirth, A., Thompson, J., Neumaier, M., von Kleist, S., and Zimmermann, W. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res., 54: 4169-4176, 1994.
28. Robbins, P. F., Kantor, J. A., Salgaller, M., Hand, P. H., Fernsten, P. D., and Schlom, J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res., 51: 3657-3662, 1991.
29. Muraro, R., Wunderlich, D., Thor, A., Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res., 45: 5769-5780. 1985.
30. Kantor, J., Irvine, K., Abrams, S., Kaufman, H., DiPietro, J., and Schlom, J. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst., 84: 1084-1091, 1992.
31. Schmitz, J., Reali, E., Hodge, J. W., Patel, A., Davis, G., Schlom, J., and Greiner, J. W. Identification of an interferon-γ-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res., 62: 5058-5064, 2002.
32. Esquivel, F., Yewdell, J., and Bennink, J. RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J. Exp. Med., 175: 163-168, 1992.
33. McLaughlin, J. P., Schlom, J., Kantor, J. A., and Greiner, J. W. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res., 56: 2361-2367, 1996.
34. Lafreniere, R., and Rosenberg, S. A. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J. Natl. Cancer Inst., 76: 309-322, 1986.
35. Aarts, W. M., Schlom, J., and Hodge, J. W. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res., 62: 5770-5777, 2002.
36. Gnant, M. F., Puhlmann, M., Bartlett, D. L., and Alexander, H. R., Jr. Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases. Ann. Surg., 230: 352-360, 1999.
37. Gnant, M. F., Puhlmann, M., Alexander. H. R., Jr., and Bartlett, D. L. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59: 3396-3403, 1999.
38. Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm. Rep., 40: 1-10, 1991.
39. Bartlett, J. G. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome. Clin. Infect. Dis., 36: 468-471. 2003.
40. Bozzette, S. A., Boer, R., Bhatnagar, V., Brower, J. L., Keeler, E. B., Morton, S. C., and Stoto, M. A. A model for a smallpox-vaccination policy. N. Engl. J. Med., 348: 416-425, 2003.
41. Ober, B. T., Bruhl, P., Schmidt, M., Wieser, V., Gritschenberger, W., Coulibaly, S., Savidis-Dacho, H., Gerencer, M., and Falkner, F. G. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara. J. Virol., 76: 7713-7723, 2002.
42. Mayr, A., Stickl, H., Muller, H. K., Danner, K., and Singer, H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's translation). Zentralbl. Bakteriol. [B], 167: 375-390, 1978.
43. Mayr, A. Historical review of smallpox, the eradication of smallpox and the attenuated smallpox MVA vaccine. Berl Munch Tierarztl. Wochenschr., 112: 322-328, 1999.
44. Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H. C., Schafer, H., and Holzner, A. MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's translation). Dtsch. Med. Wochenschr., 99: 2386-2392, 1974.
45. Carroll, M. W., and Moss. B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology, 238: 198-211, 1997.
46. Sutter, G., and Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA, 89: 10847-10851, 1992.
47. Hanke, T., McMichael, A. J., Samuel, R. V., Powell, L. A., McLoughlin, L., Crome, S. J., and Edlin, A. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine, 21: 108-114, 2002.
48. Stittelaar, K. J., Kuiken, T., de Swart, R. L., van Amerongen, G., Vos, H. W., Niesters, H. G., van Schalkwijk, P., van der Kwast, T., Wyatt, L. S., Moss, B., and Osterhaus, A. D. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine, 19: 3700-3709. 2001.
49. Hanke, T., McMichael, A. J., Mwau, M., Wee, E. G., Ceberej, I., Patel, S., Sutton, J., Tomlinson, M., and Samuel, R. V. Development of a DNA-MVA/HIVA vaccine for Kenya. Vaccine, 20: 1995-1998, 2002.
50. Harrer, T. MVA HIV vaccine reveals strong safety and immuogenicity profile in HIV infected patients. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2003.
51. Carroll, M. W., Overwijk, W. W., Chamberlain, R. S., Rosenberg, S. A., Moss, B., and Restifo, N. P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine, 15: 387-394, 1997.
52. Connolly, N. B., Harrop, R., McNeill, H., Ryan, M., Redchenko, I., Valle, J., Saunders, M., Garner, C., Welby, S., Slade, A., Kingsman, S., Carroll, M. W., and Hawkins, R. E. Phase I study of escalating doses of TroVax in patients with advanced colorectal (ACRC)-interim results. Presented at the 38th meeting of the American Society of Clinical Oncology, Abstract 1858, Orlando, FL, May 18-21, 2002.
53. Randomized Multicenter Phase II Study Evaluating Two dosing Schedules of TG4010(MVA-MUC1-1L2) in Patients with Adenocarcinoma of the Prostate. National Institutes of Health Clinical Trials Database (www.clinicaltrials.gov, NCT00040170). 2002.
54. Sutter, G., Wyatt, L. S., Foley, P. L., Bennink, J. R., and Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine, 12: 1032-1040, 1994.
55. Ramirez, J. C., Gherardi, M. M., Rodriguez, D., and Esteban, M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol., 74: 7651-7655, 2000.
56. Sharpe, S., Polyanskaya, N., Dennis, M., Sutter, G., Hanke, T., Erfle, V., Hirsch, V., and Cranage, M. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol., 82: 2215-2223, 2001.
57. Hanke, T., Blanchard, T. J., Schneider, J., Ogg, G. S., Tan, R., Becker, M., Gilbert, S. C., Hill, A. V., Smith, G. L., and McMichael, A. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type I in mice. J. Gen. Virol., 79: 83-90, 1998.
58. Feng, C. G., Blanchard, T. J., Smith, G. L., Hill, A. V., and Britton, W. J. Induction of CD8+ T-lymphocyte responses to a secreted antigen of mycobacterium tuberculosis by an attenuated vaccinia virus. Immunol. Cell. Biol., 79: 569-575, 2001.
59. Degano, P., Schneider, J., Hannan, C. M., Gilbert, S. C., and Hill, A. V. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine, 18: 623-632, 1999.
60. Vazquez-Blomquist, D., Quintana, D., and Duarte, C. A. Modified vaccinia virus Ankara (MVA) priming and fowlpox virus booster elicit stronger CTL response in mince against an HIV-1 epitope than DNA-poxvirus prime-boost approach. Presented at the 6th Latin American Congress of Immunology, Havana, Cuba, 2002.
61. Blanchard, T. J., Alcami, A., Andrea, P., and Smith, G. L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol., 79: 1159-1167, 1998.
62. Lissoni, P. Effects of low-dose recombinant interleukin-2 in human malignancies. Cancer J. Sci. Am., 3 (Suppl. 1):S115-S120, 1997.
63. Kielian, T., Nagai, E., Ikubo, A., Rasmussen, C. A., and Suzuki, T. Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol. Immunother, 48: 123-131, 1999.
64. Disis, M. L., Bernhard, H., Shiota, F. M., Hand, S. L., Gralow, J. R., Huseby, E. S., Gillis, S., and Cheever, M. A. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood, 88: 202-210, 1996.
65. Hodge, J. W., Grosenbach, D. W., Aarts, W. M., Poole, D. J., and Schlom, J. Vaccine therapy of established tumors in the absence of autoimmunity. Clin. Cancer Res., 9: 1837-1849, 2003.